Skip to main content
Premium Trial:

Request an Annual Quote

Proxeon Joins Proteomics Research Consortium

NEW YORK (GenomeWeb News) – Proxeon today said that it has joined a new research consortium focused on developing new proteomics technologies for understanding the human proteome and its role in disease.
 
The Odense, Denmark-based firm said that it is one of 12 partners in the consortium, Proteomics Specification in Time and Space (Prospects). The consortium, which is headed by Matthias Mann of the Max Planck Institute of Biochemistry, is co-funded by the European Commission with €12 million ($15.6 million) for five years within the Research Framework Programme 7.
 
Prospect’s specific focus will be on functional proteomics and mass spectrometry. The consortium was launched earlier this year, and all of the data produced through the collaboration will be made available to the scientific community through online public databases.
 
In addition to Proxeon and Max Planck, the other partners in the consortium are Thermo Fisher Scientific in Germany; the Swiss Federal Institute of Technology; the University of Cambridge and the University of Dundee in the UK; the University of Southern Denmark; the Center for Genomic Regulation in Spain; the Royal Institute of Technology in Sweden; and the Hebrew University in Israel.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.